ArticleDrug design, development and therapy2021

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.

Cong Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.